Neues zur Therapie von neuroendokrinen Tumoren des gastroenteropankreatischen Systems

Was ist neu?

Pathologische Klassifikation und Genetik Neu in der Klassifikation der neuroendokrinen Tumoren des GEP-Systems ist seit 2017 die seltene Entität des NET G3 in Abgrenzung vom NEC. Darüber hinaus wurde der Begriff des „mixed-neuroendocrine-nonneuroendocrine neoplasms“ (MINEN) eingeführt.

Therapie Über die leitlinienbasierte Therapie von NEN des GEP-Systems hinaus besteht ein „medical need“ für neue systemische Therapieansätze. Genetik, Biomarker, neue Multi-Tyrosinkinase-Inhibitoren und Chemotherapie-Protokolle sowie kombinierte multimodale Therapieansätze wie die Peptid-Receptor-ChemoRadio-Therapie (PRCRT) sind vielversprechende neue Optionen.

Neue zukünftige Therapiekonzepte und Perspektiven Die Immuntherapie bei NET des GEP-Systems zeigt bisher in der Monotherapie eine nur geringe Effektivität und sollte deshalb vorzugsweise in Kombinationstherapien in klinischen Studien weiter evaluiert werden.

Abstract

Current guidelines have been published for the diagnosis and therapy of neuroendocrine neoplasms of the gastroenteropancreatic (GEP) system [1]. Systemic therapy of inoperable advanced neuroendocrine tumors includes biotherapy with somatostatin analogas, peptid receptor radionuclide therapy (PRRT) with 177Lutetium-DOTA-TATE, chemotherapy with steptozotocin/5-fluorouracil or capecitabine/temozolomide and molecular targeted therapy with everolimus or sunitinib [1] [2]. For symptom control in patients with carcinoid syndrome biotherapy with somatostatin analogs, PRRT, loco-regional and local-ablative interventional procedures of liver metastases as well as the peripheral serotonin synthesis inhibitor telotristat Ethyl [1] [2] [3] [4] are highly effective. Novel aspects and developments in the diagnosis and treatment of neuroendocrine tumors will be discussed in this review.

Schlüsselwörter

neuroendokrine Tumoren - Biotherapie - Peptid-Rezeptor-Radionuklid-Therapie (PRRT) - Chemotherapie - molekular zielgerichtete Therapie

Key words

neuroendocrine tumors - biotherapy - peptid receptor radionuclide therapy (PRRT) - chemotherapy - molecular targeted therapy

• Literatur

• 1 Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS); Netzwerk Neuroendokrine Tumoren (NeT) e. V. (Patientenvertretung); Bundesorganisation Selbsthilfe NeuroEndokrine Tumoren e. V. (NET-sgh) (Patientenvertretung). Practice guideline neuroendocrine tumors – AWMF-Reg. 021-27. Z Gastroenterol 2018; 56: 583-681 . doi:10.1055/a-0604-2924
• 2 Auernhammer CJ, Spitzweg C, Angele MK. et al. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. Lancet Diabetes Endocrinol 2018; 6: 404-415 . doi:10.1016/S2213-8587(17)30401-1
• 3 Jin XF, Spampatti MP, Spitzweg C. et al. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important. Rev Endocr Metab Disord 2018; 19: 145-158 . doi:10.1007/s11154-018-9443-6
• 4 Hofland J, Herrera Martínez AD, Zandee WT. et al. Management of carcinoid syndrome: a systematic review and meta-analysis. Endocr Relat Cancer 2019; DOI: 10.1530/ERC-18-0495.
• 5 Klöppel G. Neuroendocrine neoplasms: Two families with distinct features unified in one classification (German version). Pathologe 2019; 40: 211-219
• 6 Rindi G, Klersy C, Albarello L. et al. Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. Neuroendocrinology 2018; 107: 375-386 . doi:10.1159/000494355
• 7 de Mestier L, Cros J, Neuzillet C. et al. Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms. Neuroendocrinology 2017; 105: 412-425 . doi:10.1159/000475527
• 8 de Mestier L, Walter T, Brixi H. et al. Comparison of temozolomide-capecitabine to 5-fluorouracile-dacarbazine in 247 patients with advanced digestive neuroendocrine tumors using propensity score analyses. Neuroendocrinology 2019; 108: 343-353 . doi:10.1159/000498887
• 9 Kunz PL, Catalano PJ, Nimeiri H. et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). J Clin Oncol 2018; 36 (Suppl. 15) 4004-4004 . doi:10.1200/JCO.2018.36.15_suppl.4004
• 10 Grillo F, Florio T, Ferraù F. et al. Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms. Endocr Relat Cancer 2018; 25: R453-R466 . doi:10.1530/ERC-17-0531
• 11 Cives M, Pelle' E, Quaresmini D. et al. The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications. Neuroendocrinology 2019; DOI: 10.1159/000497355.
• 12 Chan JA, Faris JE, Murphy JE. et al. Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET). J Clin Oncol 2017; 35 (Suppl. 04) 228-228 . doi:10.1200/JCO.2017.35.4_suppl.228
• 13 Capdevila Castillon J, Fazio NC, Lopez C. et al. Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1 / G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509). Ann Oncol 2018; 29 (Suppl. 08) Abstract 13070 . https://doi.org/10.1093/annonc/mdy293
• 14 Xu JM, Li J, Bai CM. et al. Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, single-arm, open-label, phase Ib/II trial. Clin Cancer Res 2019; DOI: 10.1158/1078-0432.CCR-18-2994.
• 15 Jin XF, Auernhammer CJ, Ilhan H. et al. Combination of 5-Fluorouracil With Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression and Radioligand Binding in Neuroendocrine Tumor Cells in Vitro. J Nucl Med 2019; 60: 1240-1246 . doi:10.2967/jnumed.118.224048
• 16 Mehnert JM, Rugo HS, O’Neil BH. et al. Pembrolizumab for patients with PD-L1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Ann Oncol 2017; 28 (Suppl. 05) Abstract 4270 . https://doi.org/10.1093/annonc/mdx368
• 17 Strosberg JR, Mizuno N, Toshihiko Doi T. et al. Pembrolizumab treatment of advanced neuroendocrine tumors: Results from the phase II KEYNOTE-158 study. J Clin Oncol 2019; 37 (Suppl. 04) 190
• 18 Yao JC, Strosberg J, Fazio N. et al. Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). Ann Oncol 2018; 29 (Suppl. 08) viii467-viii478 . https://doi.org/10.1093/annonc/mdy293.001
• 19 Weber MM, Fottner C. Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia. Oncol Res Treat 2018; 41: 306-312 . doi:10.1159/000488996
• 20 Mafficini A, Scarpa A. Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Rev 2019; 40: 506-536 . doi:10.1210/er.2018-00160
• 21 Modlin IM, Kidd M, Malczewska A. et al. The NETest: The Clinical Utility of Multigene Blood Analysis in the Diagnosis and Management of Neuroendocrine Tumors. Endocrinol Metab Clin North Am 2018; 47: 485-504